164 related articles for article (PubMed ID: 18974635)
1. Agalsidase alfa slows the decline in renal function in patients with Fabry disease.
Feriozzi S; Schwarting A; Sunder-Plassmann G; West M; Cybulla M;
Am J Nephrol; 2009; 29(5):353-61. PubMed ID: 18974635
[TBL] [Abstract][Full Text] [Related]
2. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
Tahir H; Jackson LL; Warnock DG
J Am Soc Nephrol; 2007 Sep; 18(9):2609-17. PubMed ID: 17656478
[TBL] [Abstract][Full Text] [Related]
3. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.
Feriozzi S; Torras J; Cybulla M; Nicholls K; Sunder-Plassmann G; West M;
Clin J Am Soc Nephrol; 2012 Jan; 7(1):60-9. PubMed ID: 22246281
[TBL] [Abstract][Full Text] [Related]
5. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.
Warnock DG; Thomas CP; Vujkovac B; Campbell RC; Charrow J; Laney DA; Jackson LL; Wilcox WR; Wanner C
J Med Genet; 2015 Dec; 52(12):860-6. PubMed ID: 26490103
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy and Fabry nephropathy.
Warnock DG; Daina E; Remuzzi G; West M
Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680
[TBL] [Abstract][Full Text] [Related]
7. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy and renal function in 201 patients with Fabry disease.
Schwarting A; Dehout F; Feriozzi S; Beck M; Mehta A; Sunder-Plassmann G;
Clin Nephrol; 2006 Aug; 66(2):77-84. PubMed ID: 16939062
[TBL] [Abstract][Full Text] [Related]
9. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
[TBL] [Abstract][Full Text] [Related]
10. Kidney transplantation in patients with Fabry disease.
Cybulla M; Walter KN; Schwarting A; Divito R; Feriozzi S; Sunder-Plassmann G;
Transpl Int; 2009 Apr; 22(4):475-81. PubMed ID: 19207191
[TBL] [Abstract][Full Text] [Related]
11. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.
Schiffmann R; Askari H; Timmons M; Robinson C; Benko W; Brady RO; Ries M
J Am Soc Nephrol; 2007 May; 18(5):1576-83. PubMed ID: 17409308
[TBL] [Abstract][Full Text] [Related]
12. Fabry disease: overall effects of agalsidase alfa treatment.
Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
[TBL] [Abstract][Full Text] [Related]
13. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.
Warnock DG; Ortiz A; Mauer M; Linthorst GE; Oliveira JP; Serra AL; Maródi L; Mignani R; Vujkovac B; Beitner-Johnson D; Lemay R; Cole JA; Svarstad E; Waldek S; Germain DP; Wanner C;
Nephrol Dial Transplant; 2012 Mar; 27(3):1042-9. PubMed ID: 21804088
[TBL] [Abstract][Full Text] [Related]
14. Fabry nephropathy and the case for adjunctive renal therapy.
Wanner C; Breunig F
J Am Soc Nephrol; 2007 Sep; 18(9):2426-8. PubMed ID: 17699807
[No Abstract] [Full Text] [Related]
15. Cystatin C as a marker of early changes of renal function in Fabry nephropathy.
Feriozzi S; Germain DP; Di Vito R; Legrand A; Ricci R; Barbey F
J Nephrol; 2007; 20(4):437-43. PubMed ID: 17879210
[TBL] [Abstract][Full Text] [Related]
16. Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America.
Ripeau D; Amartino H; Cedrolla M; Urtiaga L; Urdaneta B; Cano M; Valdez R; Antongiovanni N; Masllorens F
Medicina (B Aires); 2017; 77(3):173-179. PubMed ID: 28643672
[TBL] [Abstract][Full Text] [Related]
17. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Wallace EL; Goker-Alpan O; Wilcox WR; Holida M; Bernat J; Longo N; Linhart A; Hughes DA; Hopkin RJ; Tøndel C; Langeveld M; Giraldo P; Pisani A; Germain DP; Mehta A; Deegan PB; Molnar MJ; Ortiz D; Jovanovic A; Muriello M; Barshop BA; Kimonis V; Vujkovac B; Nowak A; Geberhiwot T; Kantola I; Knoll J; Waldek S; Nedd K; Karaa A; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Sakov A; Warnock DG
J Med Genet; 2024 May; 61(6):520-530. PubMed ID: 37940383
[TBL] [Abstract][Full Text] [Related]
18. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
Kampmann C; Linhart A; Devereux RB; Schiffmann R
Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
[TBL] [Abstract][Full Text] [Related]
19. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
[TBL] [Abstract][Full Text] [Related]
20. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.
Schiffmann R; Ries M; Timmons M; Flaherty JT; Brady RO
Nephrol Dial Transplant; 2006 Feb; 21(2):345-54. PubMed ID: 16204287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
